As tumor cells could evade host immunity through expression of immune checkpoint molecules, notably PD-L1 and B7-1/2, immune checkpoint blockades using monoclonal antibodies is a potential therapeutic strategy to prevent immune escape by UBC cells, thereby reactivating T cells and impeding tumor growth [70]. This evidence concerns the gene CD274 and neoplasm.